Please type a plus sign (+) inside this box	+
iodeo typo a pido digit (1) moldo ano dex	١.

12-12-01

PTO/SB/05 (03-01)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

(Only for new nonprovisional applications under 37 CFR

Under the Paperwork Reduction Act of 1995, no persons are requ	ured to res	pond to a collection of inf	ormation unless it displays a valid OMB control number.		
UTILITY PATENT APPLICATION	Attorn	ey Docket No.	LEX-0273-USA		
	Fırst Ir	nventor	Walke, et al.		
TRANSMITTAL	Title	Novel Human Kinase and Polynucleotides Encoding the Same			

Express Mail Label No. | EV017076431US

	1.50 (b/)					
	ICATION ELEMENTS 600 concerning utility patent application	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231				
X Fee Transmi     X Applicant cla     See 37 CFR     Specification (preferred arrang)     - Descriptive title     - Cross Reference     - Statement Reg.     - Reference to see or a computer     - Background of	ims small entity status.  1.27.  [Total Pages]  of the Invention  te to Related Applications  arding Fed sponsored R & Dequence listing, a table, program listing appendix the Invention  of the Invention	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i. X diskette  ii. X paper 3 pages  c. X Statements verifying identity of above copies  ACCOMPANYING APPLICATION PARTS  9. Assignment Papers (cover sheet & document(s))				
4. Drawing(s)(3 Sheets  5. Oath or Declaration a. X Unexecut b. Copy fror (for continu. i. DE sign nam 1.63  6. Application Data	ted  In a prior application (37 CFR 1.63(d)) Interest and the prior application (37 CFR 1.63(d)) Interest and the prior application, see 37 CFR 3(d)(2) and 1.33(b).  In Sheet. See 37 CFR 1.76	10. 37 CFR 3.73(b) Statement (when there is an assignee)    11. English Translation Document (if applicable)  12. Information Disclosure Statement (IDS)/PTO-1449    13. Preliminary Amendment  14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent  17. Other:  supply the requisite information below and in a preliminary amendment, apart (CIP) of prior application No.:				
Prior application information: Examiner Group Art Unit:  For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.  The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  19. CORRESPONDENCE ADDRESS						
Customer Number or Bar Code Label  (Insert Customer Number of Bar Code Label (Insert Customer Number of Artach Bar code label here)						
Name 24231						
PATENT TRADEMARK OFFICE						
Address						
City	State Zip					
Country	Telephone	Fax				
Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent) 41,866				
Signature	Lenak Schemus in Cavil W. H	DAVID WE SHELDER				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

(\$) TOTAL AMOUNT OF PAYMENT

Complete if Known				
Application Number	To be assigned			
Filing Date	12/7/2001			
First Named Inventor	Walke et al.			
Examiner Name	To be assigned			
Group Art Unit	To be assigned			
Attorney Docket No.	LEX-0273-USA			

METHOD OF PAYMENT	FEE CALCULATION (continued)				
The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to.	3. ADDITIONAL FEES  Large Small Entity Entity				
Deposit Account Number	Fee Code	Fee	Fee Code	Fee (\$)	Fee Description Fee Paid
Deposit Account Lexicon Genetics Incorporated	105	130	205	65	Surcharge - late fling fee or oath
Name Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127	50	227	25	Surcharge - late provisional filing fee or cover sheet
X Applicant claims small entity status. See 37 CFR 1 27	139	130	139	130	Non-English specification
2. Payment Enclosed:	147	2,520	147	2,520	reexamination
Check Credit card Money Order Other	112	920*	112	920*	Requesting publication of SIR prior to Examiner action
FEE CALCULATION	113	1,840*	113	1,840*	Requesting publication of SIR after
1. BASIC FILING FEE	115	110	215	55	Extension for reply within first month
Large Small Entity	116	400	216	200	Extension for reply within second month
Fee Fee Fee Fee Description	117	920	217	460	Extension for reply within third month
Code (\$) Code (\$)   Fee Paid	118	1,440	218	720	Extension for reply within fourth month
106 330 206 165 Design filing fee	128	1,960	228	980	Extension for reply within fifth month
107 510 207 255 Plant filing fee	119	320	219		Notice of Appeal
108 740 208 370 Reissue filing fee	120	320	220	160	Filing a brief in support of an appeal
114 160 214 80 Provisional filing fee	121	280	221		Request for oral hearing
	138	1,510	138		Petition to institute a public use proceeding
SUBTOTAL (1) (\$)370.00	140	110	240	55	5 Petition to revive - unavoidable
2. EXTRA CLAIM FEES	141	1,280	241	640	Petition to revive - unintentional
Fee from Extra Claims below Fee	142	1,280	242	640	Utility issue fee (or reissue)
Total Claims 2 -20**= X 0 =	143	460	243	230	Design issue fee
Independent 2 -3**= X =	144	620	244	310	Plant issue fee
Claims 2 3 =	122	130	122	130	Petitions to the Commissioner
	123	50	123	50	O Processing fee under 37 CFR 1 17(q)
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (S) Code (S)	126	180	126	180	Still
Code (\$) Code (\$)  103 18 203 9 Claims in excess of 20	581	40	581	40	Recording each patent assignment per
102 84 202 42 Independent claims in excess of 3	146	740	246	370	Filing a submission after final rejection
104 280 204 140 Multiple dependent claim, if not paid	149	740	249	370	For each additional invention to be
109 84 209 42 **Reissue independent claims over original patent	179	740	279	370	0 Request for Continued Examination (RCE)
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	169	900	169	900	Request for expedited examination of a design application
SUBTOTAL (2) (\$)		fee (spe			
**or number previously paid, if greater, For Reissues, see above	suBTC	STAL (	Basic Fılı <b>3)</b>	ing Fee F	Paid (\$)

SUBMITTED BY Complete (if applicable)								
Name (Print/Type) Lance K Ishimoto		Registration No. (Attorney/Agent)	41,866	Telephone	281-863-3333			
Signature	Lance K. Johnnoro by De	DAVIDY	1. HBEER 1. 41,071	Date	12/07/01			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Assistant Commissioner for Patents, Washington, DC 20231

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Walke et al.

U.S. Ser. No.: To be assigned Attorney Docket No.: LEX-0273-USA

Filing Date: December 7, 2001

For: NOVEL HUMAN KINASE AND

POLYNUCLEOTIDES ENCODING

THE SAME

## **VERIFIED STATEMENT**

BOX PATENT APPLICATION Commission for Patents Washington, D.C. 20231

Sir:

- I, DRENDA D. THOMAS, do declare and state as follows:
- 1. I prepared a Sequence Listing in paper and computer readable form in connection with the above-captioned patent application, both of which are being submitted herewith.
- 2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing being submitted herewith are the same.

Signed,

December 7, 2001

Date

Drenda D. Thomas